epaxal berna: Clinical Trials

6 trials of epaxal berna, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 2 Phase 2, 2 Phase 4, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2
Phase 42Completed 2
Phase 31Completed 1

Follow epaxal berna: new trials by email Literature Review of epaxal berna trials Research Report on epaxal berna

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Immunogenicity and Safety of Vaccinations in Immunocompromised Persons
Hepatitis A vaccine and tetanus vaccine - Arthritis, Rheumatoid, Spondylarthritis
CompletedUniversity of Zurich6452013-10-012016-02-25
PCV13 + Hepatitis A Vaccine for Adults
Prevenar13, Hepatitis A vaccine - Measurement of Immune Response to Prevenar13, Measurement of Immune Response to Hepatitis A
Phase 4CompletedHelsinki University Central Hospital3052013-08-242024-12-05
Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients
Epaxal Berna (virosomal hepatitis A vaccine) - Inflammatory Bowel Disease, Crohn's Disease
Phase 4CompletedAsan Medical Center4932011-04-012013-03-19
Hepatitis A Vaccine in Patients With Immunomodulating Drugs
hepatitis A vaccine ( HAVRIX or EPAXAL) - Response to Hepatitis A Vaccine
Phase 2CompletedLars Rombo682009-09-012015-11-18
Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines
Epaxal, Havrix 720 - Hepatitis A
Phase 3CompletedCrucell Holland BV3272007-03-142019-04-08
Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine
Epaxal 0.25 mL, Epaxal 0.5 mL, Havrix Junior 0.5 mL - Hepatitis A
Phase 2CompletedCrucell Holland BV3082004-06-012014-07-29

Conditions studied

Hepatitis (3)  ·  Hepatitis A (3)  ·  Arthritis, Rheumatoid (2)  ·  Colitis, Ulcerative (1)  ·  Crohn Disease (1)  ·  Inflammatory Bowel Diseases (1)  ·  Spondylarthritis (1)  ·  Vasculitis (1)

Sponsors

Crucell Holland BV (2)  ·  Asan Medical Center (1)  ·  Helsinki University Central Hospital (1)  ·  Lars Rombo (1)  ·  University of Zurich (1)

Countries

Finland (2)  ·  Sweden (2)  ·  Belgium (1)  ·  Israel (1)  ·  South Korea (1)  ·  Switzerland (1)

Top investigators

Andre Vertruyen, MD (1)  ·  Anu Kantele, Assoc. prof. (1)  ·  Christoph Hatz, Professor (1)  ·  Lars Rombo, Professor (1)  ·  Pierre van Damme, MD (1)  ·  Ron Dagan, MD (1)  ·  Shai Ashkenazi, MD (1)  ·  Suk-Kyun Yang, M.D. (1)

Results publications

PMID 24284413, PMID 27093164, PMID 30877773, PMID 37572831